BMS and Oxford BioTherapeutics join forces in TCE discovery pact
Bristol Myers Squibb (BMS) and Oxford BioTherapeutics (OBT) have forged an alliance to discover and develop new T-cell engager (TCE)…
10 Apr 2026
Roche and C4 Therapeutics to advance degrader-antibody conjugates research
Roche has signed a new collaboration agreement with C4 Therapeutics to jointly advance research in the field of degrader-antibody conjugates (DACs), aiming to introduce a new therapeutic modality for cancer.…
10 Apr 2026
Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation
Gan & Lee Pharmaceuticals has entered an exclusive licence agreement with JW Pharmaceutical for the clinical development, regulatory approval, and commercialisation of bofanglutide injection in South Korea. Bofanglutide is a…
09 Apr 2026
EverSea Medicines to acquire Hasten Biopharmaceuticals
Everest Medicines’ wholly owned subsidiary EverSea Medicines (Singapore) has signed a share purchase agreement to conditionally acquire Hasten Biopharmaceuticals, a subsidiary of Hasten Biopharmaceuticals (Asia). The acquisition aims to enhance…
09 Apr 2026
FDA seeks permanent future for rare pediatric priority review vouchers
The US Food and Drug Administration (FDA) is seeking to permanently authorise the rare pediatric disease priority review voucher (PRV) programme, putting an end to cycles of expirations and renewals…
09 Apr 2026
Shionogi secures $482m BARDA contract to tackle AMR crisis
Japanese pharma company Shionogi has secured a contract worth up to $482m with the US’s Biomedical Advanced Research and Development Authority (BARDA), as the American government looks to boost the…
09 Apr 2026
Jeito Capital secures over $1.2bn for new biopharma investments
Global independent private equity fund Jeito Capital has closed its second fund, Jeito II, surpassing its target of €1bn ($1.2bn), thereby establishing a significant new milestone for investment in European…